One of the more interesting aspects about President Donald Trump's recent tariffs is that each major industry has shown at least some degree of weakness, regardless of whether the policies have dir...

More than 2 out of 5 American adults are obese, according to the Centers for Disease Control. With this figure in mind, it's no wonder Wall Street investment banks are telling anyone who will liste...

Eli Lilly plans to make its experimental drug orforglipron in the U.S. after it secures regulatory approval, says CEO Dave Ricks.

From late 2020 to the summer of 2024, Eli Lilly & Co. (NYSE: LLY) stock was on a tear, up more than 635%.

What a difference five years can make. Just look at Eli Lilly (LLY 14.56%).

The mid-stage trial results announced by the pharmaceutical giant showed that patients taking orforglipron lost an average of 16 pounds.

Eli Lilly said its daily obesity pill met the company's goals in the first of several closely watched late-stage trials. The pill helped Type 2 diabetes patients lower their blood sugar and body we...

Some of us might be due for a windfall in the form of a $1,400 IRS payment. Today is Tax Day, and on top of that, the last day that you can apply to claim a recovery rebate credit for 2021.

Eli Lilly has shown strong financial performance, driven by key drugs like Mounjaro and Zepbound, but shares remain expensive relative to peers, justifying a 'hold' rating. Revenue, profits, and ca...

LLY's stock is attractively valued with high double digits capital appreciation prospects, driven by its promising GLP-1 therapies/ pipelines. Combined with the growing capacities and double digits...

Review Lilly's (LLY) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.

Eli Lilly's GLP-1 drugs Mounjaro and Zepbound are transforming the company. Lilly now has an obligation to take on other challenging diseases like Alzheimer's, ALS and chronic pain, said the the co...

Eli Lilly Chief Scientific Officer Dan Skovronsky said newer obesity medicines need to deliver more than just weight loss to compete with Zepbound and Wegovy. The development of pills and more pote...

If you're content with market-level returns, investing in an exchange-traded fund (ETF) is the way to go. But if not, you'll need to find stocks that hold the potential to pack more punch.

Investors should never ignore valuations when picking stocks. The price a stock trades at can drastically impact your overall returns.